Therefore, we hope to evaluate the combination therapy of a tumor-homing TRAIL variant and tumor cell-targeted PDT in combating CRC with both chemotherapeutic MDR and TRAIL resistance. The gene discussed is TNFSF10; the disease is neoplasm.